Program Faculty Scientific Committee Majed Khraishi, MD St. John's, NF Janet Pope, MD London, ON...
-
Upload
shana-joseph -
Category
Documents
-
view
215 -
download
1
Transcript of Program Faculty Scientific Committee Majed Khraishi, MD St. John's, NF Janet Pope, MD London, ON...
Program Faculty
Scientific Committee• Majed Khraishi, MD
St. John's, NF
• Janet Pope, MDLondon, ON
• Anthony Russell, MDEdmonton, AB
Participants• Carole Bertrand, MD
Terrebonne, QC
• Louis Bessette, MDQuebec, QC
• George Ecker, MDFredericton, NB
• Shahin Jamal, MDVancouver, BC
• Ariel Masetto, MDSherbrooke, QC
• Robert Charles Offer, MDPenticton, BC
Rheumatoid Arthritis
Highlights of EULAR 2013
Compiled by:Louis Bessette, MDGeorge Ecker, MDShahin Jamal, MD
Majed Khraishi, MD Robert Charles Offer, MD
Anthony Russell, MD
Burmester G, et al. Presented at EULAR 2013; Abstract #OP0067.
Effect of Methotrexate Dosing on Adalimumab Efficacy, Pharmacokinetics,
and Safety: CONCERTO StudyClinical Question: What is the effect of methotrexate (MTX) dose in combination with adalimumab in patients with early rheumatoid arthritis (RA)?
Methods: 26-week, double-blind, trial in MTX and biologic-naïve patients with active RA of < 1 year duration in the Study to Determine the Effects of Different Doses of MTX When Taken With Adalimumab in Subjects With Early RA (CONCERTO)
– Patients were randomized 1:1:1:1 to weekly oral MTX (2.5, 5, 10, or 20 mg) and received open-label adalimumab 40 mg every other week (EOW)
Burmester G, et al. Presented at EULAR 2013; Abstract #OP0067.
Proportion of Patients Achieving Low Disease Activity or Remission (DAS28[CRP]) Over Six Months: CONCERTO Study
0
40
30
70
Pa
tient
s ac
hiev
ing
DA
S2
8 <
2.6
(%
)
60
50
LDAS (primary endpoint)*
43
6057
44
20
10
DAS28 remission**
28
45
3732
Adalimumab + MTX 2.5 mg (n = 98)
Adalimumab + MTX 20 mg (n = 98)
Adalimumab + MTX 10 mg (n = 99)
Adalimumab + MTX 5 mg (n = 100)
*Low disease activity (LDAS): Disease Activity Score (DAS28) C-Reactive Protein (CRP) < 3.2;**Remission: DAS28(CRP) < 2.6. p values for trends: p = 0.005 for LDAS, p = 0.008 for remission.
Burmester G, et al. Presented at EULAR 2013; Abstract #OP0067.
Which Dose of MTX? CONCERTO: Safety Summary
Additional safety results:• Only the proportion of patients experiencing infectious AEs increased with increasing
MTX dose; serious infectious events did not increase • All other AEs occurred in < 2% of all randomized patients • No obvious trends existed pertaining to liver function tests • Infections and abnormal hair loss increased with increasing MTX dose
Treatment-Emergent Events
Adalimumab + 2.5 mg MTX(n = 98)
Adalimumab + 5 mg MTX(n = 100)
Adalimumab + 10 mg MTX(n = 99)
Adalimumab + 20 mg MTX(n = 98)
Total(n = 395)
Any adverse event (AE) 61 (62.2) 59 (59.0) 66 (66.7) 68 (69.4) 254 (64.3)
AE leading to discontinuation 3 (3.1) 0 2 (2.0) 4 (4.1) 9 (2.3)
Serious AE 5 (5.1) 2 (2.0) 3 (3.0) 7 (7.1) 17 (4.3)
Severe AE 3 (3.1) 2 (2.0) 5 (5.1) 6 (6.1) 16 (4.1)
Infectious AE 20 (20.4) 17 (17.0) 24 (24.2) 34 (34.7) 95 (24.1)
Serious infections 0 2 (2.0) 0 0 2 (0.5)
Anemia 2 (2.0) 0 1 (1.0) 2 (2.0) 5 (1.3)
Leukopenia 1 (1.0) 1 (1.0) 0 0 2 (0.5)
Injection site reaction 1 (1.0) 5 (5.0) 5 (5.1) 3 (3.1) 14 (3.5)
Burmester G, et al. Presented at EULAR 2013; Abstract #OP0067.
Effect of Methotrexate Dosing on Adalimumab Efficacy, Pharmacokinetics,
and Safety: CONCERTO StudyTake-home Messages:• In combination with adalimumab, higher dosages
of MTX (> 10 mg) are better• If there are side effects on 20 mg and/or the
patient is in remission/LDAS, it may be appropriate to reduce the MTX dose to 10 mg
Burmester G, et al. Presented at EULAR 2013; Abstract #OP0067.
Gaujoux-Viala C, et al. Presented at EULAR 2013; Abstract #THU0221.
Optimization of MTX: Data from the French ESPOIR Cohort
Clinical Question: What is the symptomatic and structural impact of MTX optimization in early arthritis (EA) in daily clinical practice over two years?
Methods:• Patients were considered “optimized” if started
> 10 mg MTX per week and > 20 mg by six months
Gaujoux-Viala C, et al. Presented at EULAR 2013; Abstract #THU0221.